Previous 10 | Next 10 |
Inotiv (NASDAQ:NOTV) is scheduled to announce FQ4 earnings results on Thursday, December 16th, after market close. The consensus EPS Estimate is -$0.13 (+18.8% Y/Y) and the consensus Revenue Estimate is $30.1M (+90.5% Y/Y). Over the last 3 months, EPS estimates have seen 0 upward revisions an...
WEST LAFAYETTE, Ind., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”) , a leading contract research organization specializing in nonclinical and analytical drug discovery and d...
WEST LAFAYETTE, Ind., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and de...
Gainers: Inotiv (NASDAQ:NOTV) +13%, Theravance Biopharma (NASDAQ:TBPH) +11%, Biofrontera (NASDAQ:BFRA) +11%, Dare Bioscience (NASDAQ:DARE) +10%, Stereotaxis (NYSE:STXS) +8%. Losers: Radius Health (NASDAQ:RDUS) -43%, Ensysce Biosciences (NASDAQ...
Inotiv (NASDAQ:NOTV): Q4 gross profit of $10.3M. Revenue of $30.1M (+90.5% Y/Y) beats by $5.61M. Press Release Backlog of $81.4 million on September 30, 2021, up 31.3% compared to $62.0 million on June 30, 2021, and up 85.8% from $43.8 million on September 30, 2020. For further details see:...
WEST LAFAYETTE, Ind., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and de...
WEST LAFAYETTE, Ind., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and de...
WEST LAFAYETTE, Ind., Nov. 10, 2021 (GLOBE NEWSWIRE) -- November 10, 2021 -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”) , a leading contract research organization specializing in nonclinical and analytical...
WEST LAFAYETTE, Ind. and INDIANAPOLIS, Nov. 05, 2021 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (or “Inotiv”) , a leading contract research organization (CRO) specializing in nonclinical and analytical drug discovery and development services and products, t...
Inotiv (NASDAQ:NOTV) shareholders approved the company's acquisition of Envigo RMS Holding Corp. Transaction consideration consists of $200M of cash and ~9.36M company common shares. The acquisition is expected to close in one or two business days, subject to closing conditions. For further...
News, Short Squeeze, Breakout and More Instantly...
WEST LAFAYETTE, Ind., June 10, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and rela...